Welcome to Few & Far Between! Chris O'Brien, CEO of Biorasi, is your host for conversations on the cutting edge - from clinical research and policymakers to rare disease advocates and industry leaders.
Episode 38: Dr. Ole Isacson, Professor of Neurology and Neuroscience, Harvard Medical School
"Artificial Intelligence is a tool that really levels up and creates almost like an equity for everybody to participate and, when used effectively, to really accelerate medicine's development." - Dr. Ole Isacson, Professor of Neurology and Neuroscience, Harvard Medical School.
Welcome to the February episode of Biorasi's Few & Far Between podcast. Join host Chris O'Brien and Dr. Ole Isacson, Professor of Neurology and Neuroscience at Harvard Medical School and Biorasi Scientific Advisory Board member, as they review the integration of AI into the world of neuroscience.
Tune in today!
Episode 37: Will Greene, Prader-Willi Syndrome patient advocate, Healthcare Engagement Lead at Roche
"The history of rare disease drug development indicates that once you start looking harder for cases, you often tend to find them." - Will Greene, Prader-Willi syndrome patient advocate and Healthcare Engagement Lead at Roche
Welcome to Biorasi's first Few & Far Between episode of 2024! Join host Chris O'Brien and guest Will Greene, Prader-Willi syndrome (PWS) patient advocate and Healthcare Engagement Lead at Roche, as they explore rare disease diagnoses and the importance of newborn screening as a public health tool.
Tune in today!
Episode 36: Zak Kohane, Department of Biomedical Informatics at Harvard Medical School
"Patients have already been exposed to these large language models (LLMs). Yes, they are aware of the risks, but they are also very aware of the benefits. And we need to engage the public in defining what those [AI] policies are." Isaac [Zak] Kohane, Professor and Chair, Department of Biomedical Informatics, Harvard Medical School
Buckle up for the latest Few & Far Between podcast! We're taking a tour of the current state of AI in healthcare and clinical research. Join host Chris O'Brien and guest Zak Kohane, Professor and Chair, Department of Biomedical Informatics, Harvard Medical School, as they spotlight the evolution of LLMs in the lives of physicians and patients.
Episode 35: Charlene Son Rigby, CEO at Global Genes
"And what I was really surprised about was that everybody was doing data collection in a different way. And I kept thinking that, gosh, there's a lot of recreation of the wheel when advocacy groups have not necessarily ever run a research study. And so I kept thinking about what opportunities do we have across rare disease to really elevate and accelerate all of this work around data collection." - Charlene Son Rigby, CEO at Global Genes
Welcome to Biorasi's Few & Far Between podcast! Join host Chris O'Brien and guest Charlene Son Rigby, CEO at Global Genes, as they discuss how to build an infrastructure for a world where clinical data is ready to be shared with all those who need it.
Episode 34: Dan Mandell, CEO at GRO Biosciences
"So we built the seatbelts before the car, so to speak, wherein we did a project to figure out ways to biocontain these organisms. And the strategy that we used actually drew from all of my past experience in computational protein design and combined it with these incredible new organisms." - Dan Mandell, CEO at GRO Biosciences
Welcome to Biorasi's Few & Far Between podcast! Join host Chris O'Brien and guest Dan Mandell, CEO at GRO Biosciences, as they discuss the latest breakthroughs in protein design - from biocontainment to creating a new amino acid alphabet.
Episode 33: Diana Sims-Silbermann, Clinician and Former Senior Trial Manager at Janssen Pharmaceuticals
Diverse & interesting
Diverse and interesting interviews with people from across the rare disease drug development world.